The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Ferrara, N., & Henzel, W. J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92678-8 · Cited by 2,268
Purification and Characterization of Hypoxia-inducible Factor 1
Wang, G. L., & Semenza, G. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1230 · Cited by 2,073
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Origins of circulating endothelial cells and endothelial outgrowth from blood
Lin, Y., Weisdorf, D. J., Solovey, A., & Hebbel, R. P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8071 · Cited by 1,531
Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Risau, W., & Flamme, I. (1995) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cb.11.110195.000445 · Cited by 1,406
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T., Maira, G., Parati, E. A., Stassi, G., Larocca, L. M., et al. (2010) · Nature · doi:10.1038/nature09557 · Cited by 1,379
Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,336
Glioblastoma stem-like cells give rise to tumour endothelium
Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K. E., Geber, A., Fligelman, B., Leversha, M., Brennan, C., & Tabar, V. (2010) · Nature · doi:10.1038/nature09624 · Cited by 1,203
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., Yancopoulos, G. D., & Thurston, G. (2006) · Nature · doi:10.1038/nature05355 · Cited by 1,032
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986
Nozawa, H., Chiu, C., & Hanahan, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601807103 · Cited by 923
Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Holmgren, E., Benjamin, R., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
O'Farrell, A.-M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W. H., Wong, L. M., Hong, W., Lee, L. B., Town, A., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2307 · Cited by 864
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Self-citationAntiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
Sleijfer, S., Ray-Coquard, I., Papai, Z., Le Cesne, A., Scurr, M., Schöffski, P., Collin, F., Pandite, L., Marreaud, S., De Brauwer, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3223 · Cited by 679
Kowanetz, M., Wu, X., Lee, J., Tan, M., Hagenbeek, T., Qu, X., Yu, L., Ross, J., Korsisaari, N., Cao, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015855107 · Cited by 663
Morgan, B., Thomas, A. L., Drevs, J., Hennig, J., Buchert, M., Jivan, A., Horsfield, M. A., Mross, K., Ball, H. A., Lee, L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.092 · Cited by 652
Bv8 regulates myeloid-cell-dependent tumour angiogenesis
Shojaei, F., Wu, X., Zhong, C., Yu, L., Liang, X.-H., Yao, J., Blanchard, D., Bais, C., Peale, F. V., van Bruggen, N., et al. (2007) · Nature · doi:10.1038/nature06348 · Cited by 644
Self-citationCrawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611
Schneider, B. P., Wang, M., Radovich, M., Sledge, G. W., Badve, S., Thor, A., Flockhart, D. A., Hancock, B., Davidson, N., Gralow, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1612 · Cited by 604
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth
Pan, Q., Chanthery, Y., Liang, W.-C., Stawicki, S., Mak, J., Rathore, N., Tong, R. K., Kowalski, J., Yee, S. F., Pacheco, G., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.10.018 · Cited by 532
Wells, S. A., Gosnell, J. E., Gagel, R. F., Moley, J., Pfister, D., Sosa, J. A., Skinner, M., Krebs, A., Vasselli, J., & Schlumberger, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6604 · Cited by 519
Anand, S., Majeti, B. K., Acevedo, L. M., Murphy, E. A., Mukthavaram, R., Scheppke, L., Huang, M., Shields, D. J., Lindquist, J. N., Lapinski, P. E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2186 · Cited by 517
Pericytes and vascular stability
VONTELL, D., ARMULIK, A., & BETSHOLTZ, C. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.10.019 · Cited by 502
Sorafenib for the Treatment of Advanced Renal Cell Carcinoma
Kane, R. C., Farrell, A. T., Saber, H., Tang, S., Williams, G., Jee, J. M., Liang, C., Booth, B., Chidambaram, N., Morse, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1249 · Cited by 474
Algire, G. H., Chalkley, H. W., Legallais, F. Y., & Park, H. D. (1945) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/6.1.73 · Cited by 472
Shojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y. G., & Ferrara, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902280106 · Cited by 471
Self-citationTemming, K., Schiffelers, R. M., Molema, G., & Kok, R. J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.10.002 · Cited by 467
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis
Murphy, E. A., Majeti, B. K., Barnes, L. A., Makale, M., Weis, S. M., Lutu-Fuga, K., Wrasidlo, W., & Cheresh, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803728105 · Cited by 455
Demerec, M., Caspari, E. W., Thoday, J. M., et al. (1947) · Advances in genetics · Cited by 412
Ebos, J. M. L., Lee, C. R., Christensen, J. G., Mutsaers, A. J., & Kerbel, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708148104 · Cited by 367
Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepulveda, J., Burrone, O., Neri, D., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10662 · Cited by 355
Pericytes limit tumor cell metastasis
Xian, X. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25705 · Cited by 345
Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
Shojaei, F., Singh, M., Thompson, J. D., & Ferrara, N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712185105 · Cited by 334
Self-citationScartozzi, M., Galizia, E., Chiorrini, S., Giampieri, R., Berardi, R., Pierantoni, C., & Cascinu, S. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn637 · Cited by 327
Advances in tenascin-C biology
Midwood, K. S., Hussenet, T., Langlois, B., & Orend, G. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0783-6 · Cited by 326
HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
Shojaei, F., Lee, J. H., Simmons, B. H., Wong, A., Esparza, C. O., Plumlee, P. A., Feng, J., Stewart, A. E., Hu-Lowe, D. D., & Christensen, J. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0489 · Cited by 319
Self-citationMetronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
Dellapasqua, S., Bertolini, F., Bagnardi, V., Campagnoli, E., Scarano, E., Torrisi, R., Shaked, Y., Mancuso, P., Goldhirsch, A., Rocca, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.4789 · Cited by 293
Mailhos, C., Modlich, U., Lewis, J., Harris, A., Bicknell, R., & Ish-Horowicz, D. (2001) · Differentiation · doi:10.1046/j.1432-0436.2001.690207.x · Cited by 288
Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms.
Epenetos, A. A., Snook, D. E., Durbin, H., Johnson, P. M., & Taylor‐Papadimitriou, J. (1986) · PubMed · Cited by 284
VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
You, W.-K., Sennino, B., Williamson, C. W., Falcón, B., Hashizume, H., Yao, L.-C., Aftab, D. T., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2527 · Cited by 259
Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy
Ellis, L. M., & Hicklin, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5287 · Cited by 257
Mancuso, P., Colleoni, M., Calleri, A., Orlando, L., Maisonneuve, P., Pruneri, G., Agliano, A., Goldhirsch, A., Shaked, Y., Kerbel, R. S., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4570 · Cited by 252
Lucio-Eterovic, A. K., Piao, Y., & de Groot, J. F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0575 · Cited by 243
Hahn, O. M., Yang, C., Medved, M., Karczmar, G., Kistner, E., Karrison, T., Manchen, E., Mitchell, M., Ratain, M. J., & Stadler, W. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5655 · Cited by 230
Garcia-Donas, J., Esteban, E., Leandro-García, L. J., Castellano, D. E., del Alba, A. G., Climent, M. A., Arranz, J. A., Gallardo, E., Puente, J., Bellmunt, J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70266-2 · Cited by 225
Hypoxia: A Link between Fibrogenesis, Angiogenesis, and Carcinogenesis in Liver Disease
Rosmorduc, O., & Housset, C. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255355 · Cited by 208
Ferrara, N. (2010) · Nature Medicine · doi:10.1038/nm1010-1107 · Cited by 203
Rhodin, J. A. G., & Fujita, H. (1989) · PubMed · Cited by 180
Gao, D., Nolan, D., McDonnell, K., Vahdat, L., Benezra, R., Altorki, N., & Mittal, V. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.05.001 · Cited by 178
Role of myeloid cells in tumor angiogenesis and growth
Shojaei, F., Zhong, C., Wu, X., Yu, L., & Ferrara, N. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.06.003 · Cited by 167
Self-citationCascone, T., Herynk, M. H., Xu, L., Du, Z., Kadara, H., Nilsson, M. B., Oborn, C. J., Park, Y.-Y., Erez, B., Jacoby, J. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42405 · Cited by 164
Xu, L., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Chung, D. C., Lauwers, G. Y., Samuel, R., Shellito, P., Czito, B. G., Lin, P.-C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2099 · Cited by 161
Li, L., Wartchow, C. A., Danthi, S. N., Shen, Z., Dechene, N., Pease, J., Choi, H. S., Doede, T., Chu, P., Ning, S., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.10.057 · Cited by 161
FDA Approves Sorafenib for Patients With Inoperable Liver Cancer
Lang, L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.037 · Cited by 159
The role of the hypoxia-inducible factor in tumor metabolism growth and invasion.
Brahimi‐Horn, C., & Pouysségur, J. (2006) · PubMed · Cited by 154
The involvement of endothelial progenitor cells in tumor angiogenesis
Ribatti, D. (2004) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2004.tb00319.x · Cited by 149
Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
Rapisarda, A., & Melillo, G. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.03.002 · Cited by 142
Antibody-Drug Conjugate Targets
Teicher, B. A. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909790192365 · Cited by 142
McKeage, M. J., von Pawel, J., Reck, M., Jameson, M. B., Rosenthal, M. A., Sullivan, R., Gibbs, D. D., Mainwaring, P. N., Serke, M. H., Lafitte, J. J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604808 · Cited by 127
Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas
Rowand, J. L., Martin, G., Doyle, G. V., Miller, M. C., Pierce, M. S., Connelly, M. C., Rao, C., & Terstappen, L. W. M. M. (2007) · Cytometry Part A · doi:10.1002/cyto.a.20364 · Cited by 126
Nagengast, W. B., Hooge, M. N. L., Oosting, S. F., den Dunnen, W. F. A., Warnders, F.-J., Brouwers, A. H., de Jong, J. R., Price, P., Hollema, H., Hospers, G. A. P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1088 · Cited by 113
Drug Insight: vascular disrupting agents and angiogenesis—novel approaches for drug delivery
Cooney, M. M., van Heeckeren, W., Bhakta, S., Ortiz, J., & Remick, S. C. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0663 · Cited by 112
Gerber, H., Wu, X., Yu, L., Wiesmann, C., Liang, X. H., Lee, C. V., Fuh, G., Olsson, C., Damico, L. A., Xie, D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611492104 · Cited by 109
Lila, A. S. A., Kizuki, S., Doi, Y., Suzuki, T., Ishida, T., & Kiwada, H. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.02.023 · Cited by 107
Embryonic Angiogenesis: A Review
Wilting, J., & Christ, B. (1996) · Die Naturwissenschaften · doi:10.1007/bf01143056 · Cited by 99
Porta, C., Paglino, C., AMICI, M. D., Quaglini, S., Sacchi, L., Imarisio, I., & Canipari, C. (2010) · Kidney International · doi:10.1038/ki.2009.552 · Cited by 99
Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy
Smith, J. K., Mamoon, N. M., & Duhé, R. J. (2003) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/000000003772462298 · Cited by 96
Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences
Broxterman, H. J., Lankelma, J., & Hoekman, K. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00026-8 · Cited by 91
Yang, S. X., Steinberg, S. M., Nguyen, D., Wu, T. D., Modrusan, Z. D., & Swain, S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4762 · Cited by 90
Targeting Anticancer Drugs to Tumor Vasculature Using Cationic Liposomes
Lila, A. S. A., Ishida, T., & Kiwada, H. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0110-1 · Cited by 89
Conclusions and Future Perspectives
Fanelli, R. (2011) · doi:10.1002/9781118000816.ch19 · Cited by 70
Taraboletti, G., Rusnati, M., Ragona, L., & Colombo, G. (2010) · Oncotarget · doi:10.18632/oncotarget.200 · Cited by 70
Antibody drug-conjugates targeting the tumor vasculature
Gerber, H., Senter, P. D., & Grewal, I. S. (2009) · mAbs · doi:10.4161/mabs.1.3.8515 · Cited by 69
Iordanov, M. S., & Magun, B. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25801 · Cited by 69
Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer
Tan, E.-H., Goss, G. D., Salgia, R., Besse, B., Gandara, D. R., Hanna, N. H., Yang, J. C., Thertulien, R., Wertheim, M. S., Mazières, J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318220c93e · Cited by 67
Loupakis, F., Falcone, A., Masi, G., Fioravanti, A., Kerbel, R. S., Tacca, M. D., & Bocci, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3051 · Cited by 64
HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
Shojaei, F., Simmons, B. H., Lee, J. H., Lappin, P. B., & Christensen, J. G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.026 · Cited by 63
Self-citationVEGF inhibitors for the treatment of neovascular age-related macular degeneration
Barakat, M., & Kaiser, P. K. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902855316 · Cited by 62
Hansen, T. F., Christensen, R. D., Andersen, R. F., Spindler, K. G., Johnsson, A., & Jakobsen, A. K. M. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1382-6 · Cited by 61
CD133+ Glioblastoma Stem-Like Cells Induce Vascular Mimicry in Vivo
Chiao, M., Yang, Y., Cheng, W.-Y., Shen, C., & Ko, J. (2011) · Current Neurovascular Research · doi:10.2174/156720211796558023 · Cited by 59
Molecular Predictors of Response to Antiangiogenesis Therapies
Gerger, A., LaBonte, M. J., & Lenz, H. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318212db3c · Cited by 55
Jayson, G. C., Mulatero, C., Ranson, M., Zweit, J., Jackson, A., Broughton, L., Wagstaff, J., Håkansson, L., Groenewegen, G., Lawrance, J., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.11.021 · Cited by 54
Gorgels, T. G. M. F., Waarsing, J. H., Herfs, M., Versteeg, D., Schoensiegel, F., Sato, T., Schlingemann, R. O., Ivandic, B., Vermeer, C., Schurgers, L. J., et al. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0782-y · Cited by 52
Short interfering RNA (siRNA), a novel therapeutic tool acting on angiogenesis
Hadj-Slimane, R., Lepelletier, Y., LOPEZ, N., Garbay, C., & Raynaud, F. (2007) · Biochimie · doi:10.1016/j.biochi.2007.06.012 · Cited by 43
Vasculogenensis, angiogenesis and special features of tumor blood vessels
Hiratsuka, S. (2010) · Frontiers in bioscience · doi:10.2741/3796 · Cited by 43
Circulating biomarkers of bevacizumab activity in patients with breast cancer
Denduluri, N., Yang, S. X., Berman, A. W., Nguyen, D., Liewehr, D. J., Steinberg, S. M., & Swain, S. M. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.1.5337 · Cited by 37
Axitinib in the Treatment of Metastatic Renal Cell Carcinoma
Ho, T. H., & Jonasch, E. W. (2011) · Future Oncology · doi:10.2217/fon.11.107 · Cited by 36
Comparative genomics analysis of human sequence variation in the UGT1A gene cluster
Maitland, M. L., Grimsley, C., Kuttab-Boulos, H., Witonsky, D., Kasza, K., Yang, L., Roe, B. A., & Rienzo, A. D. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500351 · Cited by 34
Antiangiogenic anticancer strategy based on nanoparticulate systems
Yoncheva, K., & Momekov, G. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.585155 · Cited by 28
Inhibition of Vascular Endothelial Growth Factor Receptor Signaling in Angiogenic Tumor Vasculature
Backer, M. V., Hamby, C. V., & Backer, J. M. (2009) · Advances in genetics · doi:10.1016/s0065-2660(09)67001-2 · Cited by 18
Cited by
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
Zhao, Y., & Adjei, A. A. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0465 · Cited by 558
Eccles, S. A., Aboagye, E. O., Ali, S., Anderson, A. S., Armes, J., Berditchevski, F., Blaydes, J. P., Brennan, K., Brown, N. J., Bryant, H. E., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3493 · Cited by 421
Microenvironment and tumor cell plasticity: An easy way out
Taddei, M. L., Giannoni, E., Comito, G., & Chiarugi, P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.042 · Cited by 264
Metadata
- Authors
- Shojaei, F.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 320
- Issue
- 2
- Pages
- 130-137
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2070800535
- Cited by
- 348
- References
- 111
- FWCI
- 18.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.